Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; Lake, D. E.; Goldfarb, S. B.; Patil, S.; Covey, A.; Berger, M. F.; Lacouture, M. E.; Norton, L.; Hudis, C. A.; Baselga, J.; Chandarlapaty, S.; Dickler, M. N. |
| Abstract Title: | Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) |
| Meeting Title: | 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 75 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2014 Dec 9-13 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-01 |
| Language: | English |
| ACCESSION: | WOS:000356730200167 |
| DOI: | 10.1158/1538-7445.sabcs14-pd5-3 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium -- DEC 09-13, 2014 -- San Antonio, TX -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work